Lol the strategic review doesn't mean anything... they have already announced what they wont be selling anymore and have indicated less than 20% impact. Sure they will downsize and it will have some costs but will also save money.
Income generated moving forward wont be as good until they get other income streams via diversified products that wont cause issues with regulator... but I still think they will be profitable. So after first quarter results...we will see some indication of this. Very undervalued still factoring in a few negatives market has factored in. E.g. potential no st Andrew's. Short term target is .2 medium and long term will depend on products they can diversify to and results.
imo only.
